Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Potential of anti-amyloid drugs for treating Alzheimer’s disease

Oscar López • 4 Apr 2022
AAN 2022
Alzheimer’s Disease Dementia Mild Cognitive Impairment Aducanumab Antibodies

Oscar López, MD, FAAN, University of Pittsburgh, Pittsburgh, PA, talks about the approval of aducanumab for treating patients with early-stage Alzheimer’s disease (AD) and discusses the potential of anti-amyloid drugs for treating early-stage AD. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

More from Oscar López

Blood biomarkers for the diagnosis of Alzheimer's disease
1:02
Blood biomarkers for the diagnosis of Alzheimer's disease
Oscar López • 4 Apr 2022
Predictive factors of progression from mild cognitive impairment to dementia
1:26
Predictive factors of progression from mild cognitive impairment to dementia
Oscar López • 4 Apr 2022
Diagnosing mild cognitive impairment
1:35
Diagnosing mild cognitive impairment
Oscar López • 4 Apr 2022

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals